Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study.

ABSTRACT:

Background

One of the most significant challenges in patients with medulloblastoma is reducing the dose of craniospinal irradiation (CSI) to minimize neurological sequelae in survivors. Molecular characterization of patients receiving lower than standard dose of CSI therapy is important to facilitate further reduction of treatment burden.

Methods

We conducted DNA methylation analysis using an Illumina Methylation EPIC array to investigate molecular prognostic markers in 38 patients with medulloblastoma who were registered in the Japan Pediatric Molecular Neuro-Oncology Group and treated with reduced-dose CSI.

Results

Among the patients, 23 were classified as having a standard-risk and 15 as high-risk according to the classic classification based on tumor resection rat

SUBMITTER: Fukuoka K 

PROVIDER: S-EPMC10521425 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature